



COBRA ANNOUNCES MANUFACTURING AGREEMENT FOR TNFERADE™

Keele, UK: Cobra Biomanufacturing Plc (AIM: CBF), the international manufacturer of biopharmaceuticals, today announces that it has entered into a manufacturing development agreement with GenVec, Inc. for TNFerade™, GenVec's lead product candidate. The agreement will cover technology transfer, scale-up, and validation of the manufacturing process for TNFerade through cGMP consistency lots that will be produced at Cobra's facility in Oxford, United Kingdom.

"GenVec selected Cobra based upon their expertise in viral manufacturing and the experience of key staff members with commercial biopharmaceutical products. Activities under this agreement will establish a clear path for the submission of the chemistry, manufacturing, and controls (CMC) portion of a biological license application for TNFerade as GenVec works towards the completion of our current Phase III clinical trial," said Dr. Bryan Butman, GenVec's Senior Vice President of Vector Operations.

"We are delighted to work with GenVec on this exciting project. TNFerade has demonstrated great potential for the treatment of pancreatic cancer," added Simon Saxby, Cobra Biomanufacturing's Chief Operating Officer. "This agreement will leverage Cobra's significant experience manufacturing recombinant adenovirus under cGMP conditions."

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade™ is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. Additional clinical trials are in progress in rectal cancer, head and neck cancer and melanoma. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and influenza. Additional information about GenVec is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission.

About TNFerade™

TNFerade is an adenovector, or DNA carrier, which contains the gene for tumor necrosis factor-alpha (TNF_α), an immune system protein with potent and well-documented anti-cancer effects, for direct injection into tumors. After administration, TNFerade stimulates the production of TNF_α in the tumor. GenVec is developing TNFerade for use in combination with radiation and/or chemotherapy for the treatment of various cancers.

For further information, please contact:

Cobra Biomanufacturing Plc
Simon Saxby, Chief Operating Officer

Tel: +44 (0) 1782 714 181

Buchanan Communications
Tim Anderson/Rebecca Skye Dietrich

Tel: +44 (0) 207 466 5000

College Hill Life Sciences
Gemma Price

Tel: +44 (0) 20 7457 2020

Seymour Pierce (NOMAD & Broker)
Stuart Lane

Tel: +44 (0) 20 107 8000

Notes to Editors:

About Cobra Biomanufacturing Plc:

Cobra Biomanufacturing Plc is a leading international manufacturer of biopharmaceuticals to the lifescience industry. Founded in 1992, Cobra provides innovative manufacturing solutions to the biopharmaceutical industry covering DNA, virus, cellular therapeutics and recombinant protein products.

Cobra has developed a range of unique, patented technologies, which underpin a successful revenue generating contract manufacturing business.

Cobra floated on the Alternative Investment Market of the London Stock Exchange in June 2002 raising £7 million and raised a further £5.2 million in May 2003 in order to further expand capacity in Oxford UK. Since floatation the Company has grown turnover from \$6m to \$20m providing expert manufacturing services across the world with over 80% of revenues currently originating from the US market.

www.cobrabio.com